In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerulean Pharma Inc.

Division of Dare Bioscience Inc.
www.ceruleanrx.com

Latest From Cerulean Pharma Inc.

Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy

Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing out of licensing discussions and which the Japanese firm says will strengthen its presence in biologics for renal disorders and other high-need areas.

M & A Biologics

Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio

Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.

Financing StartUps and SMEs

Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.
Deals Business Strategies

Deals Shaping The Medical Industry, April 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Tempo Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dare Bioscience Inc.
  • Senior Management
  • Christopher Guiffre, Pres. & CEO
    Gregg Beloff, CFO
    Scott Eliasof, PhD, SVP, CSO
    Tiffany Crowell, VP, Clinical Operations
  • Contact Info
  • Cerulean Pharma Inc.
    Phone: (781) 996-4300
    35 Gatehouse Dr.
    Waltham, MA 02451
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register